Malignant pheochromocytomas and paragangliomas: a diagnostic challenge

被引:41
作者
Gimm, Oliver [1 ,2 ,3 ]
DeMicco, Catherine [4 ]
Perren, Aurel [5 ]
Giammarile, Francesco [6 ]
Walz, Martin K. [7 ,8 ]
Brunaud, Laurent [9 ]
机构
[1] Linkoping Univ, Dept Surg, Div Endocrine Surg, S-58185 Linkoping, Sweden
[2] Cty Council Ostergotland, Dept Surg, Linkoping, Sweden
[3] Linkoping Univ, Div Surg, Dept Clin & Expt Med, Fac Hlth Sci, S-58185 Linkoping, Sweden
[4] Fac Med, Lab Anat & Cytologie Pathol, Marseille, France
[5] Univ Bern, Inst Pathol, Bern, Switzerland
[6] Univ Lyon 1, Ctr Hosp Lyon Sud, Hosp Civils Lyon, Fac Charles Merieux Lyon Sud,EMR 3738, Lyon, France
[7] Kliniken Essen Mitte, Klin Chirurg, Essen, Germany
[8] Kliniken Essen Mitte, Zentrum Minimal Invas Chirurg, Essen, Germany
[9] Univ Nancy, Dept Digest Hepatobiliary & Endocrine, Surg CHU Nancy Brabois, Hop Adultes, Nancy, France
关键词
Pheochromocytoma; Paraganglioma; Malignancy; Diagnosis; Therapy; POSITRON-EMISSION-TOMOGRAPHY; GLAND SCALED SCORE; COMPARATIVE GENOMIC HYBRIDIZATION; OF-THE-ART; METAIODOBENZYLGUANIDINE MIBG SCINTIGRAPHY; EXTRAADRENAL SYMPATHETIC PARAGANGLIOMAS; CHROMAFFIN GRANULE TRANSMITTERS; ENDOCRINE NEOPLASIA TYPE-2; REGION-SPECIFIC ANTIBODIES; GASTRIC STROMAL SARCOMA;
D O I
10.1007/s00423-011-0880-x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare disorders arising from the adrenal gland, from the glomera along parasympathetic nerves or from paraganglia along the sympathetic trunk. According to the WHO classification, malignancy of PCCs and PGLs is defined by the presence of metastases at non-chromaffin sites distant from that of the primary tumor and not by local invasion. The overall prognosis of metastasized PCCs/PGLs is poor. Surgery offers currently the only change of cure. Preferably, the discrimination between malignant and benign PCCs/PGLs should be made preoperatively. Methods This review summarizes our current knowledge on how benign and malignant tumors can be distinguished. Conclusion Due to the rarity of malignant PCCs/PGLs and the obvious difficulties in distinguishing benign and malignant PCCs/PGLs, any patient with a PCC/PGL should be treated in a specialized center where a multidisciplinary setting with specialized teams consisting of radiologists, endocrinologist, oncologists, pathologists and surgeons is available. This would also facilitate future studies to address the existing diagnostic and/or therapeutic obstacles.
引用
收藏
页码:155 / 177
页数:23
相关论文
共 225 条
[1]   IMMUNOCYTOCHEMISTRY OF PARAGANGLIOMAS - VALUE OF STAINING FOR S-100 PROTEIN AND GLIAL FIBRILLARY ACID PROTEIN IN DIAGNOSIS AND PROGNOSIS [J].
ACHILLES, E ;
PADBERG, BC ;
HOLL, K ;
KLOPPEL, G ;
SCHRODER, S .
HISTOPATHOLOGY, 1991, 18 (05) :453-458
[2]   Treatment of Malignant Pheochromocytoma [J].
Adjalle, R. ;
Plouin, P. F. ;
Pacak, K. ;
Lehnert, H. .
HORMONE AND METABOLIC RESEARCH, 2009, 41 (09) :687-696
[3]   Pheochromocytoma: Current approaches and future directions [J].
Adler, Joel T. ;
Meyer-Rochow, Goswin Y. ;
Chen, Herbert ;
Benn, Diana E. ;
Robinson, Bruce G. ;
Sippel, Rebecca S. ;
Sidhu, Stan B. .
ONCOLOGIST, 2008, 13 (07) :779-793
[4]   Size of the Tumor and Pheochromocytoma of the Adrenal Gland Scaled Score (PASS): Can They Predict Malignancy? [J].
Agarwal, Amit ;
Mehrotra, Prateek K. ;
Jain, Manoj ;
Gupta, Sushil K. ;
Mishra, Anjali ;
Chand, Gyan ;
Agarwal, Gaurav ;
Verma, A. K. ;
Mishra, S. K. ;
Singh, Uttam .
WORLD JOURNAL OF SURGERY, 2010, 34 (12) :3022-3028
[5]   Malignant pheochromocytoma - State of the field with future projections [J].
Ahlman, Hakan .
PHEOCHROMOCYTOMA, 2006, 1073 :449-464
[6]   Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma [J].
Algeciras-Schimnich, Alicia ;
Preissner, Carol M. ;
Young, William F., Jr. ;
Singh, Ravinder J. ;
Grebe, Stefan K. G. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (01) :91-95
[7]   Genetic testing in pheochromocytoma or functional paraganglioma [J].
Amar, L ;
Bertherat, J ;
Baudin, E ;
Ajzenberg, C ;
Bressac-de Paillerets, B ;
Chabre, O ;
Chamontin, B ;
Delemer, B ;
Giraud, S ;
Murat, A ;
Niccoli-Sire, P ;
Richard, SP ;
Rohmer, V ;
Sadoul, JL ;
Strompf, L ;
Schlumberger, M ;
Bertagna, X ;
Plouin, PF ;
Jeunemaitre, X ;
Gimenez-Roqueplo, AP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8812-8818
[8]   Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas [J].
Amar, Laurence ;
Baudin, Eric ;
Burnichon, Nelly ;
Peyrard, Severine ;
Silvera, Stephane ;
Bertherat, Jerome ;
Bertagna, Xavier ;
Schlumberger, Martin ;
Jeunemaitre, Xavier ;
Gimenez-Roqueplo, Anne-Paule ;
Plouin, Pierre-Francois .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (10) :3822-3828
[9]   Malignant pheochromocytomas and paragangliomas - The importance of a multidisciplinary approach [J].
Andersen, Kim Francis ;
Altaf, Rahim ;
Krarup-Hansen, Anders ;
Kromann-Andersen, Bjarne ;
Horn, Thomas ;
Christensen, Niels Juel ;
Hendel, Helle Westergren .
CANCER TREATMENT REVIEWS, 2011, 37 (02) :111-119
[10]   Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma [J].
Astuti, D ;
Latif, F ;
Dallol, A ;
Dahia, PLM ;
Douglas, F ;
George, E ;
Sköldberg, F ;
Husebye, ES ;
Eng, C ;
Maher, ER .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (01) :49-54